SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics moves up on joining hand with ICT

17 Mar 2020 Evaluate

Lasa Supergenerics is currently trading at Rs. 40.80, up by 1.90 points or 4.88% from its previous closing of Rs. 38.90 on the BSE.

The scrip opened at Rs. 40.80 and has touched a high and low of Rs. 40.80 and Rs. 40.00 respectively. So far 13741 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 49.70 on 03-Mar-2020 and a 52 week low of Rs. 9.48 on 06-Aug-2019.

Last one week high and low of the scrip stood at Rs. 40.80 and Rs. 34.30 respectively. The current market cap of the company is Rs. 165.94 crore.

The promoters holding in the company stood at 36.80%, while Institutions and Non-Institutions held 0.03% and 63.17% respectively.

Lasa Supergenerics has joined hand with Institute of Chemical Technology (ICT) to develop Favipiravir for treatment of COVID19 which has currently emerged as pandemic.

Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease (COVID-2019). It possesses activity against many RNA viruses. It is a guanine analogue approved for influenza treatment. It can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus, and a recent study reported its activity against 2019-nCoV.

Lasa Supergenerics is pioneer and amongst the leading players in the manufacturing of APIs in India through its catalyst chemistry expertise and fully backward integrated unit.

Lasa Supergenerics Share Price

8.47 0.33 (4.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×